Lung cancer: Are we up to the challenge?

Luca Esposito, Daniele Conti, Ramyasri Ailavajhala, Nansie Khalil, Antonio Giordano

Research output: Contribution to journalArticle

Abstract

Lung cancer is the leading cause of cancer deaths worldwide among both men and women, with more than 1 million deaths annually. Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers. Although recent advances have been made in diagnosis and treatment strategies, the prognosis of NSCLC patients is poor and it is basically due to a lack of early diagnostic tools. However, in the last years genetic and biochemical studies have provided more information about the protein and gene's mutations involved in lung tumors. Additionally, recent proteomic and microRNA's approaches have been introduced to help biomarker discovery. Here we would like to discuss the most recent discoveries in lung cancer pathways, focusing on the genetic and epigenetic factors that play a crucial role in malignant cell proliferation, and how they could be helpful in diagnosis and targeted therapy.

Original languageEnglish
Pages (from-to)513-518
Number of pages6
JournalCurrent Genomics
Volume11
Issue number7
Publication statusPublished - 2010

    Fingerprint

Keywords

  • Diagnostic tools for lung cancer
  • Epigenetics of lung cancer
  • Lung cancer
  • Oncogenes
  • Oncosuppressors

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Esposito, L., Conti, D., Ailavajhala, R., Khalil, N., & Giordano, A. (2010). Lung cancer: Are we up to the challenge? Current Genomics, 11(7), 513-518.